In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus

Authors

  • Essam Mohammed Janahi Department of Biology, College of Science, University of Bahrain, P.O. Box 32038, Kingdom of Bahrain
  • Anupam Dhasmana Research Cell, Amity University Lucknow Campus, Lucknow-226028, UP, India; Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India
  • Vandana Srivastava Department of Zoology, Lucknow University, Lucknow-226007, UP, India
  • Aditya Narayan Sarangi Biomedical Informatics Centre, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow-226014, UP, India
  • Sana Raza Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India; Department of Biosciences, Integral University, Lucknow-226026, UP, India
  • Jamal M. Arif Department of Biochemistry, University of Hail, Hail-2440, Saudi Arabia
  • Madan Lal Bramha Bhatt Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India
  • Mohtashim Lohani Department of Radiotherapy, King George Medical University, Lucknow-226003, UP, India; Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia
  • Mohammed Yahya Areeshi Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia
  • Anand Murari Saxena Department of Zoology, Lucknow University, Lucknow-226007, UP, India
  • Shafiul Haque Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan-45142, Saudi Arabia; Department of Biosciences, Jamia Millia Islamia (A Central University), New Delhi-110025, India

DOI:

https://doi.org/10.17179/excli2016-719

Keywords:

Zika virus, HLA, vaccine, prophylactic, immunogens, B-/T-cell

Abstract

Zika virus (ZIKV) is a mosquito-borne flavivirus distributed all over Africa, South America and Asia. The infection with the virus may cause acute febrile sickness that clinically resembles dengue fever, yet there is no vaccine, no satisfactory treatment, and no means of evaluating the risk of the disease or prognosis in the infected people. In the present study, the efficacy of the host's immune response in reducing the risk of infectious diseases was taken into account to carry out immuno-informatics driven epitope screening strategy of vaccine candidates against ZIKV. In this study, HLA distribution analysis was done to ensure the coverage of the vast majority of the population. Systematic screening of effective dominant immunogens was done with the help of Immune Epitope & ABCPred databases. The outcomes suggested that the predicted epitopes may be protective immunogens with highly conserved sequences and bear potential to induce both protective neutralizing antibodies, T & B cell responses. A total of 25 CD4+ and 16 CD8+ peptides were screened for T-cell mediated immunity. The predicted epitope "TGLDFSDLYYLTMNNKHWLV" was selected as a highly immunogenic epitope for humoral immunity. These peptides were further screened as non-toxic, immunogenic and non-mutated residues of envelop viral protein. The predicted epitope could work as suitable candidate(s) for peptide based vaccine development. Further, experimental validation of these epitopes is warranted to ensure the potential of B- and T-cells stimulation for their efficient use as vaccine candidates, and as diagnostic agents against ZIKV.

Downloads

Published

2017-01-13

How to Cite

Janahi, E. M., Dhasmana, A., Srivastava, V., Sarangi, A. N., Raza, S., Arif, J. M., … Haque, S. (2017). In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus. EXCLI Journal, 16, 63–72. https://doi.org/10.17179/excli2016-719

Issue

Vol. 16 (2017)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).